Insider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys $25,526.15 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper bought 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. This trade represents a 0.04 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock opened at $21.76 on Monday. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29. The company has a market cap of $2.39 billion, a P/E ratio of -8.37 and a beta of -0.04. The firm has a 50-day moving average of $21.66 and a 200-day moving average of $21.27.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $3.30 million. As a group, research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC raised its stake in shares of NewAmsterdam Pharma by 35.6% during the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after purchasing an additional 86,712 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in NewAmsterdam Pharma by 1,231.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock valued at $3,972,000 after acquiring an additional 221,305 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of NewAmsterdam Pharma by 176.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after acquiring an additional 14,280 shares during the period. State Street Corp increased its stake in shares of NewAmsterdam Pharma by 168.7% during the 3rd quarter. State Street Corp now owns 37,915 shares of the company’s stock worth $629,000 after purchasing an additional 23,805 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after purchasing an additional 1,399 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on NAMS shares. Needham & Company LLC reduced their price objective on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. HC Wainwright reissued a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, Scotiabank raised their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.